Cmp-2-Keto-3-Deoxy-Octulosonic Acid is an investigational drug.
There have been 8 clinical trials for Cmp-2-Keto-3-Deoxy-Octulosonic Acid.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 11th 2018.
The most common disease conditions in clinical trials are Carcinoma, Leukemia, Lymphoid, and Hepatic Insufficiency. The leading clinical trial sponsors are National Cancer Institute (NCI), Louisiana State University Health Sciences Center in New Orleans, and Bayer.
There are six US patents protecting this investigational drug and sixty-five international patents.